These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18760744)

  • 1. [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval].
    Giuliano F; Vicaut E; Jeanpetit Y
    Prog Urol; 2008 Sep; 18(8):536-42. PubMed ID: 18760744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials.
    Shabsigh R; Burnett AL; Eardley I; Sharlip ID; Ellsworth PI; Garcia CS; Natanegara F; Ahuja S
    BJU Int; 2005 Oct; 96(6):857-63. PubMed ID: 16153217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
    Zhang SX; Gao P
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study].
    Martín-Morales A; Gutiérrez Hernández PR; Meijide Rico F; Arrondo Arrondo JL; Turbí Disla C
    Actas Urol Esp; 2010 Apr; 34(4):356-64. PubMed ID: 20470698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
    Salonia A; Gallina A; Zanni G; Briganti A; Dehò F; Saccà A; Suardi N; Barbieri L; Guazzoni G; Rigatti P; Montorsi F
    Eur Urol; 2008 Mar; 53(3):564-70. PubMed ID: 17761385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction.
    Afif-Abdo J; Teloken C; Damião R; Koff W; Wroclawski E; Yamasaki R; Torres LO; Sabaneeff J; Faria G; Pompeo AC; Cortado P; Glina S
    BJU Int; 2008 Sep; 102(7):829-34. PubMed ID: 18537952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study.
    Wespes E; Moncada I; Schmitt H; Jungwirth A; Chan M; Varanese L
    BJU Int; 2007 Jan; 99(1):121-6. PubMed ID: 17227498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tadalafil and patients preference in the treatment of erectile dysfunction].
    Hu JL; Chen B
    Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1145-8. PubMed ID: 17201266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours].
    Deng SM
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):857-60. PubMed ID: 18998474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature.
    Morales AM; Casillas M; Turbi C
    Int J Impot Res; 2011; 23(1):1-8. PubMed ID: 21191396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.